Services for Researchers

Animal Models for the Evaluation of Experimental Therapies and Vaccines

Prioritization and Approval Process

• The likelihood that services will contribute significantly to the eventual development and/or evaluation of a product of high priority.
• Public health impact within the scope of the Division of Microbiology and Infectious Diseases’ responsibilities.
• Innovation; i.e., the aspects of the product that will achieve what current control measures are not able to, that will improve the capability of existing control measures or that will result in a product that is as useful or better than existing control measures.
• Previous use of DMID resources for assessment of the same or similar product. Repeat use of DMID resources may be undertaken with strong justification.
• Need for this support beyond availability of support from other sources.
• Competing priorities/availability of contract resources.